Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint

Pfizer Inc. (PFE) announced positive top-line results of a Phase 3 study examining the use of Lyrica or pregabalin Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients aged one month to less than four years.

from RTT - Biotech https://ift.tt/2wN20p9
via IFTTT